Hansa Biopharma Q2 FY26 operating loss widens to SEK 174.1 million; revenue slips to SEK 48.1 million

  • Hansa Biopharma posted Q2 revenue of SEK 48.1 million; operating loss widened to SEK 174.1 million.
  • Net loss widened to SEK 260.5 million; EPS improved to SEK -2.56.
  • Idefirix product sales eased to SEK 46.8 million; cash and short-term investments rose to SEK 552.8 million.
  • H1 revenue fell to SEK 82.7 million; net cash from operations swung to SEK 250.5 million.
  • Signed a €115 million out-licensing deal with SERB for Idefirix in Europe and MENA; received €110 million upfront in early July.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 20260721:BIT:0801:0) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.